

About the author

Arthur Declercq started his academic journey in Biomedical Sciences in 2016. In 2018 he got selected for the honours program in life sciences focused on: “Optimization of CD4+ T cells infection with varicella- zoster virus in vitro”



During his MSc he got the opportunity to combine his interest in immunology with his passion for programming through the development of AI-models for enhanced epitope identification, a project he continued as Predoctoral Researcher within CompOmics at VIB-UGent Center for Medical Biotechnology. He contributed to several tools such as MS²PIP, MS²Rescore, TIMS²Rescore and developed his own epitope prediction tool MHC-3PO. With his contributions to MS²Rescore and its benefits to identify potential vaccine candidates he won the PhD innovation café in 2023.

Funding

Research Foundation Flanders (FWO) –
SB grant 1SE3724N

Ground control

PROMOTOR

Prof. Dr. Lennart Martens

VIB - Ghent University

CO-PROMOTOR

Prof. Dr. Francis Impens

VIB - Ghent University

MENTOR

Dr. Ralf Gabriels

VIB - Ghent University

Mission Crew

CHAIR

Prof. Dr. Jo Vandesompele

Ghent University

COMMITTEE SECRETARY

Dr. An Staes

VIB - Ghent University

JURY MEMBER

Dr. Susan Klaeger

Genentech Inc

JURY MEMBER

Prof. Dr. Sven Nahnsen

Tübingen University

JURY MEMBER

Dr. Fabien Henri Thery

VIB - Ghent University


JURY MEMBER

Prof. Dr. Bart Mesuere

Ghent University

EPITOPE ODYSSEY

Data-driven tools to extend the known
immunopeptide universe



Arthur Declercq

Thesis submitted to fulfill the requirements for the
degree of Doctor in Health Sciences
2024-2025

Summary

Just as astronomers map the stars to understand the universe, scientists map proteins to understand life. Proteins are the workhorses of our cells, carrying out the countless processes that keep us alive. Studying them—proteomics—has transformed biology and medicine, by revealing how our bodies function, why diseases arise, and how therapies can overcome them.

Within proteomics, a key branch called immunopeptidomics, investigates small protein fragments called epitopes. These fragments are displayed on the surface of every cell, acting as signals for the immune system to detect infections, mutations, or cancers. Identifying epitopes is therefore essential for designing effective vaccines and personalized immunotherapies.

My PhD focused on developing AI-powered tools to help identify these epitopes more easily. I worked on MS²PIP, which predicts how epitopes fragment in mass spectrometers, and MS²Rescore, which uses these spectrum predictions and other prediction tools to boost epitope discovery.

I expanded this work with TIMS²Rescore, tailored to newer instruments such as timsTOF, which not only boosts the discovery of epitopes but also helps reveal proteins circulating in the blood and gut. Most recently, I created MHC-3PO, a deep-learning model that can predict likely epitopes—including chemically modified ones—directly from protein sequence.

Together, these tools help expand the epitope landscape, bringing us closer to better vaccines, improved immunotherapies, and a deeper understanding of how our immune system protects us.

Key publications

- Declercq, A. et al. (2022). MS2Rescore boosts immunopeptide identification. Mol Cell Proteomics.
- Declercq, A. et al. (2023). Updated MS2PIP web server for proteomics. Nucleic Acids Res.
- Buur, L.M. & Declercq, A. et al. (2023). MS2Rescore 3.0: modular platform for peptide IDs. J Proteome Res.
- Declercq, A. & Devreese, R. et al. (2025). TIMS2Rescore: optimized rescoring pipeline. J Proteome Res.

Contact



Arthur Declercq



Arthur.Declercq@UGent.be



linkedin.com/in/arthur-declercq



arthurdeclercq.bio



github.com/ArthurDeclercq



orcid.org/0000-0002-9376-1399

Take home messages

1. Epitopes are tiny protein fragments on every cell surface that help the immune system distinguish healthy cells from infected or cancer cells
2. With advanced software, we can identify these epitopes more precisely and reliably.
3. These epitopes provide actionable targets for pathogen vaccines and personalised cancer treatments.